1-(1,8-naphthyridin-2-yl)ethan-1-one | 1188433-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(1,8-naphthyridin-2-yl)ethan-1-one
• 英文别名: 1-(1,8-Naphthyridin-2-YL)ethanone
• CAS: 1188433-77-3
• 化学式: C₁₀H₈N₂O
• mdl: MFCD08062662
• 分子量: 172.186
• InChiKey: DUMNPJGEKDCKPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(1,8-naphthyridin-2-yl)ethan-1-one 在 (S)-3,3'-bis(2,4,6-tri-iso-propylphenyl)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 148.25h， 生成 (R)-N-(2-(1,8-naphthyridin-2-yl)-2-phenylethyl)aniline
  参考文献：
  名称：

  不对称质子催化催化对映选择性合成α-手性氮杂杂芳基乙胺

  摘要：

  报道了从乙烯基取代的N-杂环和苯胺直接合成手性氮杂杂芳基乙胺的对映体。手性磷酸（CPA）催化剂可促进脱氮使aza-Michael加成芳烃，从而产生前手性环外芳基烯胺，该胺在重新芳构化后会发生不对称质子化。该反应在前手性中心可容纳各种N-杂环，亲核试剂和取代基，从而产生高对映选择性的产物。DFT研究支持了基于催化剂诱导的LUMO降低的简便亲核加成，并从离子对前手性中间体进行了位点选择性，限速，分子内不对称质子转移。

  DOI：

  10.1002/anie.201806956

文献信息

• [EN] HERBICIDAL COUMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES
  申请人：SYNGENTA LTD

  公开号：WO2009115788A1

  公开（公告）日：2009-09-24

  The present invention relates to novel herbicidal [l,8]-naphthyridines of Formula (Ia) or (Ib), or an agronomically acceptable salt of said compound wherein R2, R3, R4, R5,R6,R7, R8, n, m, X and Q are as defined herein. The invention further relates to processes and intermediates for the preparation of the [l,8]-naphthyridines, to compositions which comprise the herbicidal compounds, and to their use for controlling weeds, in particular in crops of useful plants.

  本发明涉及具有以下式(Ia)或(Ib)的新型除草剂[l,8]-萘啉，或者该化合物的农业上可接受的盐，其中R2、R3、R4、R5、R6、R7、R8、n、m、X和Q如本文所定义。该发明还涉及制备[l,8]-萘啉的过程和中间体，包括含有除草剂化合物的组合物，以及它们在控制杂草方面的用途，特别是在有用植物作物中。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243525A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及用于预防和治疗抑制OGA有益的疾病的这些化合物和组合物的使用，例如tau病变病，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Batchelor Mark James

  公开号：US20110178069A1

  公开（公告）日：2011-07-21

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、减少IGIF和IFN-γ产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• HERBICIDAL COMPOUNDS
  申请人：Mitchell Glynn

  公开号：US20110021352A1

  公开（公告）日：2011-01-27

  The present invention relates to novel herbicidal [1,8]-naphthyridines of Formula (Ia) or (Ib), or an agronomically acceptable salt of said compound wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n, m, X and Q are as defined herein. The invention further relates to processes and intermediates for the preparation of the [1,8]-naphthyridines, to compositions which comprise the herbicidal compounds, and to their use for controlling weeds, in particular in crops of useful plants.

  本发明涉及新型除草剂[1,8]-萘啶类化合物，其化学式为(Ia)或(Ib)，或其农业上可接受的盐，其中R2、R3、R4、R5、R6、R7、R8、n、m、X和Q如本文所定义。本发明还涉及制备[1,8]-萘啶类化合物的工艺和中间体，包括含有除草剂化合物的组合物，以及它们在控制杂草方面的用途，特别是在有用植物的作物中。
• HERBICIDAL COUMPOUNDS
  申请人：Syngenta Limited

  公开号：EP2265120A1

  公开（公告）日：2010-12-29